Trial · NCT06942910
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
NCT06942910, Phase 2, Active not recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria. Trials, record NCT06942910. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06942910
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
- NCT number
- NCT06942910
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 224 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- Zibotentan/Dapagliflozin, Dapagliflozin
- First posted
- 2025-04-24
- Last updated
- 2026-09-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline | At Week 12 | To estimate the efficacy of zibotentan and dapagliflozin in FDC versus dapagliflozin alone in reducing albuminuria |
| Secondary | Change in log-transformed Urinary Protein to Creatinine Ratio (UPCR) from baseline | At Week 12 | To estimate the efficacy of zibotentan and dapagliflozin in FDC versus dapagliflozin alone in reducing proteinuria |
| Secondary | Change in systolic and diastolic blood pressure (BP) from baseline | At Week 12 | To estimate the efficacy of zibotentan and dapagliflozin in FDC versus dapagliflozin alone in reducing systolic and diastolic BP |
| Secondary | Number of participants experiencing adverse events | From Week 1 (Day 1) until Follow-up visit (Week 18, Day 112) | To assess the safety and tolerability of treatment with zibotentan and dapagliflozin in FDC compared to dapagliflozin alone during 12 weeks of treatment and 4 weeks of safety follow-up |
| Other | Change in estimated Glomerular Filtration Rate (eGFR) from baseline | At Week 12 | To explore the effect of zibotentan and dapagliflozin in FDC versus dapagliflozin alone to slow decline in kidney function, as measured by eGFR |
| Other | Proportion of participants achieving Urine Protein to Creatinine Ratio (UPCR) < 1000 mg/g and > 30% reduction from baseline | Across the visits from Week 2 (Day 14) up to Week 12 (Day 84) | To explore the effect of zibotentan and dapagliflozin in FDC versus dapagliflozin alone to reduce proteinuria, as measured by the proportion of participants achieving UPCR \< 1000 mg/g and \> 30% reduction from baseline |
| Other | Proportion of participants achieving Urinary Albumin to Creatinine Ratio (UACR) < 300 mg/g | Across the visits from Week 2 (Day 14) up to Week 12 (Day 84) | To explore the effect of zibotentan and dapagliflozin in FDC versus dapagliflozin alone to reduce albuminuria, as measured by the proportion of participants achieving UACR \< 300 mg/g |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06942910
GET https://conductscience.org/api/trials/v1/NCT06942910/registered